# SKYE earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SKYE) · [Earnings tab](https://www.lopjlb.com/stock/SKYE?tab=earnings)

Updated: 2026-11-09T04:22:18

Quarters analyzed: 6

## Cross-quarter narrative

Across six quarterly updates, Skye Bioscience moved from reporting vague guidance in 2024 Q3 to delivering concrete trial progress and expanding its obesity program by 2025 Q4. The company completed enrollment of 136 patients in the CBeyond Phase IIa study in Q4 2024, confirmed completion ahead of schedule in Q1 2025, and repeatedly emphasized that topline data are expected late Q3/early Q4 2025. Pre‑clinical work showed additive weight‑loss effects when nimacimab is combined with tirzepatide, later reinforced by a modest 3 % incremental loss in a semaglutide combo in Q3 2025. Building on these signals, Skye announced higher‑dose Phase II combos, FDA feedback, a Halozyme sub‑cutaneous formulation and early antibody‑peptide conjugate data in Q4 2025. Financially, cash balances grew from $68.4 M at end‑2024 to a runway extending through Q1 2027, later adjusted to Q4 2026 as the program broadened. The company also discontinued the SBI‑100 program in Q4 2024 to focus resources on nimacimab. Overall, the narrative shifts from uncertainty to a clearer, data‑driven development trajectory with expanding combination and formulation strategies.

## Latest CallCard · Q4

Skye Bioscience advances nimacimab obesity program with CBeyond expansion to higher doses, FDA feedback, Halozyme subcutaneous formulation, and early antibody-peptide conjugate data; cash runway through Q4 2026.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights achievements: combinatio

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q4:** Skye Bioscience advances nimacimab obesity program with CBeyond expansion to higher doses, FDA feedback, Halozyme subcutaneous formulation, and early antibody-peptide conjugate data; cash runway through Q4 2026.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights achievements: combinatio
- **2025 Q3:** Skye Bioscience reports positive Phase 2a CBEYOND data for Nimazumab + semaglutide showing ~3% additional weight loss, improved body composition, and durability; advancing higher-dose Phase 2 combo and maintenance strategies with cash runway into 2027.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepa
- **2025 Q2:** Skye Bioscience reports Phase IIa CBeyond enrollment complete, top-line data expected late Q3/early Q4; preclinical data shows nimacimab combination with tirzepatide yields 44% weight loss and durable maintenance; cash runway through Q1 2027.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emph
- **2025 Q1:** Skye Bioscience completed Phase 2a CBeyond enrollment ahead of schedule, extended to 52 weeks; preclinical data shows Nimacimab's allosteric CB1 inhibition yields weight loss comparable to small molecules with additive effect to tirzepatide (31.5% in DIO), preserves lean mass; cash runway through Q1
- **2024 Q4:** Skye Bioscience completed enrollment of 136 patients in CBeyond Phase IIa trial for nimacimab, expects topline data late Q3/early Q4 2025, extended trial to 52 weeks, and plans Phase IIb by Q2 2026. Cash $68.4M at year-end 2024. Discontinued SBI-100 to focus on nimacimab. Manufacturing scale-up unde
- **2024 Q3:** —

## Theme arcs

- **Clinical trial execution** (improving): Enrollment completed and topline data anticipated, with positive Phase IIa readouts.
- **Combination therapy efficacy** (improving): Preclinical and early clinical data show additive weight‑loss with tirzepatide and semaglutide.
- **Dose escalation** (new): Higher‑dose Phase II combos introduced in Q3 2025.
- **Formulation development** (new): Sub‑cutaneous Halozyme platform and antibody‑peptide conjugate data disclosed in Q4 2025.
- **Financial runway** (stable): Cash runway extended to Q1 2027 then to Q4 2026 as program expands.
- **Portfolio focus** (resolved): SBI‑100 discontinued in Q4 2024 to concentrate on nimacimab.

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SKYE`